Fundraising FoxOncoSynergy
Stamford, US · Delaware corporation · 3 known investors
Find your way into OncoSynergy
Sign up to see every warm intro you have to OncoSynergy
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OncoSynergy team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OncoSynergy is a clinical-stage immuno-oncology company developing monoclonal antibody therapeutics, including a pan-CD29 antibody and a PD1-targeting antibody. It operates in the biotech and cancer drug development space.
Founders & leadership
WS
W. Shawn CarbonellCofounder & Chief Scientific Officer2022–2025W. Shawn Carbonell is executive officer and director of OncoSynergy, a clinical-stage immuno-oncology company developing monoclonal antibody therapeutics. He previously trained in neurosurgery and founded a biotech company focused on integrin-targeting cancer therapeutics that advanced to Phase I clinical trials.
RD
Robert DunkleNamed on SEC filing
Board
AS
HS
Hen Suh ParkBoard director
Investors · 3
Also in the syndicate · 2
Korea Information & CommunicationNLabs
Reported raises · per SEC filings
Form D private placements$33.3M disclosed across 4 rounds · 2018–2026
▶$6.6MraisedMay 2026 · 5 investors · BiotechnologyRule 506(b)
▶$6.6MraisedMay 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allen SalmasiDirector
- Anne-Marie CarbonellExecutive Officer, Director
- Hen Suh ParkDirector
- Offering amount
- $8.2M
- Amount sold
- $6.6M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedMay 2022 · 4 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMay 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colin FosterDirector
- Allen SalmasiDirector
- Anne-Marie CarbonellExecutive Officer, Director
- Hen Suh ParkDirector
- Offering amount
- $7.3M
- Amount sold
- $3.5M
- Sales commissions
- $46.6K
- Placement agents
- Kelson Capital
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedSep 2020 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anne-Marie CarbonellExecutive Officer, Director
- Colin FosterDirector
- Robert DunkleDirector
- Allen SalmasiDirector
- Hen Suh ParkDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedMay 2018 · 23 investors · BiotechnologyRule 506(b)
▶$20MraisedMay 2018 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert DunkleDirector
- W. Shawn CarbonellExecutive Officer, Director
- Allen SalmasiDirector
- Hen Suh ParkDirector
- Anne-Marie CarbonellExecutive Officer
- Offering amount
- $21M
- Amount sold
- $20M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
OncosenxOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
OncoC4OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.
Oncusp TherapeuticsOnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
Companies working in the same space as OncoSynergy.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $700K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does OncoSynergy do?
- OncoSynergy is a clinical-stage immuno-oncology company developing monoclonal antibody therapeutics, including a pan-CD29 antibody and a PD1-targeting antibody. It operates in the biotech and cancer drug development space.
- Who founded OncoSynergy?
- OncoSynergy was founded by Anne-Marie Carbonell, W. Shawn Carbonell.
- Who are OncoSynergy's investors?
- OncoSynergy's investors include Connecticut Innovations.
- How much funding has OncoSynergy raised?
- OncoSynergy has disclosed $33.3M raised across 4 rounds.
- Where is OncoSynergy headquartered?
- OncoSynergy is headquartered in Stamford, US.